Clinical Trial Update: Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa [Phase 3]

View source ↗

Summary

The Phase III trial of UF-021 for retinitis pigmentosa was terminated before completion, with efficacy and safety data not finalized.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinitis Pigmentosa

Drugs mentioned

• UF-021

Snippet

Sponsor: R-Tech Ueno, Ltd. | Conditions: Retinitis Pigmentosa | Phase 3 | Status: TERMINATED